On September 21, 2017, the Comprehensive Economic and
Trade Agreement (CETA) signed between the European Union (EU) and Canada
provisionally entered into force in Canada. Among other things, this
agreement seeks to harmonize laws relating to protection of intellectual
property in the EU and Canada, thereby bringing about a number of changes in
Canadian patent law, particularly with respect to laws relating to the issuance
of patents covering pharmaceutical products. One of the biggest changes
is the implementation of a Certificate of Supplementary Protection (CSP) Regime
in Canada for pharmaceutical products that have been granted regulatory
approval.
No comments:
Post a Comment